Anaconda Biomed raised $56 million to support product development and clinical work for its stroke tech platform, including completion of the Athena pivotal study under an investigational device exemption. The funding is intended to advance the Ana Funnel catheter and progress it through later regulatory and commercialization steps. For interventional stroke care, device pipeline momentum can shift competitive positioning quickly, especially when pivotal studies conclude and the field moves toward premarket pathways. The round signals continued capital support for catheter-based platforms that focus on safety and performance in clinically meaningful endpoints.